Source link : https://newshealth.biz/health-news/fda-tosses-rems-restriction-on-thyroid-cancer-drug/
(MedPage Today) — A risk evaluation and mitigation strategies (REMS) program is no longer required for the thyroid cancer therapy vandetanib (Caprelsa), the FDA announced on Thursday. The agency had required the safety program for vandetanib… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/117646 Author : Publish date : 2025-09-25 20:21:00 Copyright for syndicated content belongs to the linked […]
The post FDA Tosses REMS Restriction on Thyroid Cancer Drug first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-25 20:21:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8